Tuyen Bui
YOU?
Author Swipe
View article: Supplementary Materials and Methods from Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time
Supplementary Materials and Methods from Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time Open
This file contains the description of supplementary materials and methods that is referred to in the manuscript
View article: Supplemental Figures and Figure legends from Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time
Supplemental Figures and Figure legends from Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time Open
This File contains all the supplemental figures and figure legends referred to in the main text.
View article: Supplementary Materials and Methods from Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers
Supplementary Materials and Methods from Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers Open
This file contains all the supplementary materials and methods referred to in the text.
View article: Hybrid molecule SA-10 and its PLGA nanosuspension protect human and rodent retinal ganglion cells against neuronal injury
Hybrid molecule SA-10 and its PLGA nanosuspension protect human and rodent retinal ganglion cells against neuronal injury Open
View article: IL-6 predicts CDK4/6 inhibitor resistance, identifying STAT3 as a target in HR + /HER2-negative metastatic breast cancer
IL-6 predicts CDK4/6 inhibitor resistance, identifying STAT3 as a target in HR + /HER2-negative metastatic breast cancer Open
View article: ĐẶC ĐIỂM GEN MÃ HÓA KHÁNG NGUYÊN NadA, NHBA CÁC CHỦNG Neisseria meningitidis NHÓM HUYẾT THANH B PHÂN LẬP Ở VIỆT NAM GIAI ĐOẠN 2014 - 2024
ĐẶC ĐIỂM GEN MÃ HÓA KHÁNG NGUYÊN NadA, NHBA CÁC CHỦNG Neisseria meningitidis NHÓM HUYẾT THANH B PHÂN LẬP Ở VIỆT NAM GIAI ĐOẠN 2014 - 2024 Open
Bệnh nhiễm trùng do não mô cầu là một bệnh truyền nhiễm cấp tính do N. meningitidis gây ra, bệnh tiến triển nhanh, có tỷ lệ tử vong cao nếu không điều trị kịp thời. Sử dụng vắc xin được xem là một trong những biện pháp hiệu quả nhất để phò…
View article: ĐÁNH GIÁ TỶ LỆ TỒN LƯU KHÁNG THỂ IgG KHÁNG VI RÚT DENGUE, VI RÚT HANTA VÀ VI RÚT CHIKUNGUNYA TRÊN NGƯỜI KHỎE MẠNH TỪ 18 TUỔI TRỞ LÊN BẰNG KỸ THUẬT ELISA TẠI MỘT SỐ KHU VỰC THUỘC TỈNH HÀ GIANG VÀ LAI CHÂU
ĐÁNH GIÁ TỶ LỆ TỒN LƯU KHÁNG THỂ IgG KHÁNG VI RÚT DENGUE, VI RÚT HANTA VÀ VI RÚT CHIKUNGUNYA TRÊN NGƯỜI KHỎE MẠNH TỪ 18 TUỔI TRỞ LÊN BẰNG KỸ THUẬT ELISA TẠI MỘT SỐ KHU VỰC THUỘC TỈNH HÀ GIANG VÀ LAI CHÂU Open
SEROLOGICAL SURVEY OF DENGUE VIRUS, HANTAVIRUS AND CHIKUNGUNYA VIRUS ANTI ANTIBODIES IN RESIDENTS OF SOME DISTRICTS OF HA GIANG AND LAI CHAU PROVINCES Objectives: To assess the serological prevalence of Dengue virus, Hantavirus and Chikung…
View article: ĐÁNH GIÁ CHẤT LƯỢNG SỐNG CỦA BỆNH NHÂN UNG THƯ CỔ TỬ CUNG GIAI ĐOẠN IB-III SAU ĐIỀU TRỊ TẠI BỆNH VIỆN K
ĐÁNH GIÁ CHẤT LƯỢNG SỐNG CỦA BỆNH NHÂN UNG THƯ CỔ TỬ CUNG GIAI ĐOẠN IB-III SAU ĐIỀU TRỊ TẠI BỆNH VIỆN K Open
Mục tiêu: Nghiên cứu nhằm đánh giá chất lượng sống và một số yếu tố ảnh hưởng đến chất lượng sống của bệnh nhân ung thư cổ tử cung sau điều trị tại bệnh viện K. Đối tượng: Gồm 142 bệnh nhân ung thư cổ tử cung giai đoạn IB-III điều trị bằng…
View article: Supplementary Table 2 from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer
Supplementary Table 2 from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer Open
Immune cell subset annotations and antibodies used for analysis.
View article: Supplementary Figures and Legends from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer
Supplementary Figures and Legends from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer Open
This file includes all the 8 supplementary figures and their corresponding figure legends referred to in the main text.
View article: Supplementary Table 1 from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer
Supplementary Table 1 from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer Open
Clinical and pathological characteristics of the 53 TNBC
View article: Supplementary Methods from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer
Supplementary Methods from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer Open
This file contains all the information pertaining to supplementary methods that were referred to in the supplementary data.
View article: Supplementary Methods from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer
Supplementary Methods from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer Open
This file contains all the information pertaining to supplementary methods that were referred to in the supplementary data.
View article: Supplementary Table 1 from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer
Supplementary Table 1 from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer Open
Clinical and pathological characteristics of the 53 TNBC
View article: Supplementary Figures and Legends from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer
Supplementary Figures and Legends from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer Open
This file includes all the 8 supplementary figures and their corresponding figure legends referred to in the main text.
View article: Data from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer
Data from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer Open
Cyclin E is a regulatory subunit of CDK2 that mediates S phase entry and progression. The cleavage of full-length cyclin E (FL-cycE) to low–molecular weight isoforms (LMW-E) dramatically alters substrate specificity, promoting G1
View article: Supplementary Table 2 from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer
Supplementary Table 2 from Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer Open
Immune cell subset annotations and antibodies used for analysis.
View article: Supplementary Table 1 from Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers
Supplementary Table 1 from Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers Open
This file contains Supplementary Table 1, pertaining to the proteomic classification of RPPA antibodies
View article: Supplementary Table 1 from Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers
Supplementary Table 1 from Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers Open
This file contains Supplementary Table 1, pertaining to the proteomic classification of RPPA antibodies
View article: Supplementary Materials and Methods from Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers
Supplementary Materials and Methods from Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers Open
This file contains all the supplementary materials and methods referred to in the text.
View article: Supplementary Materials and Methods from Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers
Supplementary Materials and Methods from Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers Open
This file contains all the supplementary materials and methods referred to in the text.
View article: Data from Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers
Data from Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers Open
Cyclin-dependent-kinase-4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) is standard of care for patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC). However, resistance to CDK4/6is plus ET remains…
View article: Supplemental Figures and Figure Legends from Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers
Supplemental Figures and Figure Legends from Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers Open
The attached file contains 12 Supplemental Figures and Figure Legnds
View article: Supplemental Figures and Figure Legends from Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers
Supplemental Figures and Figure Legends from Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers Open
The attached file contains 12 Supplemental Figures and Figure Legnds
View article: Supplemental Figures and Figure Legends from Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers
Supplemental Figures and Figure Legends from Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers Open
The attached file contains 12 Supplemental Figures and Figure Legnds
View article: Supplementary Materials and Methods from Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers
Supplementary Materials and Methods from Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers Open
This file contains all the supplementary materials and methods referred to in the text.
View article: Supplemental Figures and Figure Legends from Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers
Supplemental Figures and Figure Legends from Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers Open
The attached file contains 12 Supplemental Figures and Figure Legnds
View article: Data from Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers
Data from Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers Open
Cyclin-dependent kinases 4/6 inhibitor (CDK4/6i) plus endocrine therapy (ET) is standard of care for patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC). However, resistance to CDK4/6is plus ET remain…
View article: Supplementary Materials and Methods from Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers
Supplementary Materials and Methods from Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers Open
This file contains all the supplementary materials and methods referred to in the text.
View article: Supplementary Table 1 from Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers
Supplementary Table 1 from Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers Open
This file contains Supplementary Table 1, pertaining to the proteomic classification of RPPA antibodies